Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care

BACKGROUND: New direct-acting antiviral (DAA) therapy has dramatically increased cure rates for patients infected with hepatitis C virus (HCV), but has also substantially raised treatment costs. AIM: The aim of this analysis was to evaluate the therapeutic benefit and net costs (i.e. efficiency fron...

Descripción completa

Detalles Bibliográficos
Autores principales: Younossi, Zobair M., Park, Haesuk, Dieterich, Douglas, Saab, Sammy, Ahmed, Aijaz, Gordon, Stuart C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072943/
https://www.ncbi.nlm.nih.gov/pubmed/27741116
http://dx.doi.org/10.1097/MD.0000000000005048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072943/
https://www.ncbi.nlm.nih.gov/pubmed/27741116
http://dx.doi.org/10.1097/MD.0000000000005048

Ejemplares similares